Esophageal Cancer

Oncology
27
Pipeline Programs
22
Companies
45
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
2
18
1
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
360%
Monoclonal Antibody
240%
+ 29 programs with unclassified modality

Competitive Landscape

22 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
1 program
1
ProsurePhase 41 trial
Active Trials
NCT00790140Unknown120Est. Jul 2010
Alliance Pharmaceuticals
7 programs
5
2
cisplatinPhase 31 trial
cisplatinPhase 31 trial
capecitabinePhase 25 trials
carboplatinPhase 21 trial
carboplatinPhase 21 trial
+2 more programs
Active Trials
NCT05247905Active Not Recruiting31Est. Oct 2033
NCT01032850Terminated15Est. Aug 2017
NCT00891878Completed12Est. Jan 2013
+8 more trials
Pfizer
PfizerNEW YORK, NY
1 program
1
Irinotecan hydrochloride trihydratePhase 2/31 trial
Active Trials
NCT00160875Completed54Est. Mar 2011
Bristol Myers Squibb
2 programs
1
carboplatin, 5FU, Taxol and radiationPhase 21 trial
NivolumabN/AMonoclonal Antibody1 trial
Active Trials
NCT06499298Completed64Est. Apr 2025
NCT00139633Unknown25Est. Jun 2005
CT
2 programs
1
1
Utidelone and anlotinibPhase 2Small Molecule1 trial
TQB6411 InjectionPhase 1/21 trial
Active Trials
NCT07367516RecruitingEst. Mar 2027
NCT05866510UnknownEst. Apr 2024
Sanofi
SanofiPARIS, France
2 programs
2
5-FluorouracilPhase 21 trial
OxaliplatinPhase 21 trial
Active Trials
NCT00525915Completed126Est. Mar 2013
NCT00256269Terminated4Est. Feb 2007
Genentech
GenentechCA - Oceanside
2 programs
2
BevacizumabPhase 2Monoclonal Antibody1 trial
ErlotinibPhase 2Small Molecule1 trial
Active Trials
NCT00394433Completed38Est. Oct 2016
NCT00539617Terminated7Est. May 2011
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
Afatinib and PaclitaxelPhase 21 trial
Active Trials
NCT01522768Completed42Est. Feb 2023
Ipsen
IpsenChina - Tianjin
1 program
1
Cabozantinib 40 MGPhase 21 trial
Active Trials
NCT05007613Completed24Est. Dec 2024
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
DKN-01Phase 21 trial
Active Trials
NCT03818997Withdrawn0Est. Apr 2022
BeOne Medicines
BeOne MedicinesCA - San Carlos
1 program
1
LBL-007Phase 21 trial
Active Trials
NCT06010303Active Not RecruitingEst. May 2026
Bayer
BayerLEVERKUSEN, Germany
1 program
1
Sorafenib, administered orallyPhase 21 trial
Active Trials
NCT00917462Completed35Est. Aug 2018
DS
Daiichi SankyoChina - Shanghai
1 program
1
exatecan mesylatePhase 21 trial
Active Trials
NCT00017212CompletedEst. Sep 2003
Astex Pharmaceuticals
Astex PharmaceuticalsUK - Cambridge
1 program
1
rubitecanPhase 21 trial
Active Trials
NCT00005876Unknown
LP
Lee's PharmaceuticalChina - Guangzhou
1 program
1
anti-PD-L1 antibodyPhase 1/21 trial
Active Trials
NCT04460066Unknown70Est. Jul 2023
City Therapeutics
City TherapeuticsMA - Cambridge
2 programs
1
erlotinib hydrochloridePhase 11 trial
ctDNA detectionN/A1 trial
Active Trials
NCT06792786RecruitingEst. Dec 2027
NCT00566800Unknown
AN
Adlai NortyeNORTH BRUNSWICK, NJ
1 program
1
AN0025Phase 11 trial
Active Trials
NCT05191667SuspendedEst. Dec 2025
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
Pulsed low dose rate radiotherapyPhase 11 trial
Active Trials
NCT06760676Not Yet RecruitingEst. Jul 2027
Genomics
GenomicsUK - Oxford
2 programs
Establishment of Molecular Classification Models for Early Diagnosis of Digestive System CancersN/A1 trial
Methylation Biomarkers for Pioneering Early Esophageal Cancer DetectionN/A1 trial
Active Trials
NCT05431621Completed2,430Est. Jul 2023
NCT06895551Completed1,069Est. Feb 2025
Verona Pharma
Verona PharmaUK - London
1 program
BIRC3N/A1 trial
Active Trials
NCT04269083Unknown128Est. Aug 2024
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
Contrast swallow radiography, endoscopyN/A1 trial
Active Trials
NCT00642525Completed55Est. Oct 2007
Knight Therapeutics
Knight TherapeuticsQC - Montréal
1 program
Screening with swallowable esophageal cell-collection devicesN/A1 trial
Active Trials
NCT06335966Active Not Recruiting110Est. Dec 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
AbbottProsure
Alliance Pharmaceuticalscisplatin
Alliance Pharmaceuticalscapecitabine
Alliance Pharmaceuticalscisplatin
PfizerIrinotecan hydrochloride trihydrate
BeOne MedicinesLBL-007
Chia Tai TianQing Pharmaceutical GroupUtidelone and anlotinib
Alliance Pharmaceuticalscapecitabine
IpsenCabozantinib 40 MG
RocheDKN-01
Boehringer IngelheimAfatinib and Paclitaxel
Alliance Pharmaceuticalscapecitabine
Alliance Pharmaceuticalscapecitabine
Alliance Pharmaceuticalscapecitabine
BayerSorafenib, administered orally

Showing 15 of 45 trials with date data

Clinical Trials (45)

Total enrollment: 6,203 patients across 45 trials

NCT00790140AbbottProsure

Trial of Enteral Nutrition Enriched With Eicosapentaenoic Acid (EPA) in Upper Gastrointestinal Cancer Surgery

Start: Jul 2005Est. completion: Jul 2010120 patients
Phase 4Unknown
NCT00052910Alliance Pharmaceuticalscisplatin

Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer

Start: Dec 2002Est. completion: Dec 2016546 patients
Phase 3Completed
NCT00024102Alliance Pharmaceuticalscapecitabine

Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer

Start: Sep 2001Est. completion: Nov 2012633 patients
Phase 3Completed
NCT00003118Alliance Pharmaceuticalscisplatin

Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus

Start: Oct 1997Est. completion: Mar 200056 patients
Phase 3Completed
NCT00160875PfizerIrinotecan hydrochloride trihydrate

Pre-operative Chemo (CPT11, Cisplatin), Radiotherapy, Plus Surgery for Resectable Esophageal Cancer

Start: Apr 2009Est. completion: Mar 201154 patients
Phase 2/3Completed
NCT06010303BeOne MedicinesLBL-007

A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Start: Nov 2023Est. completion: May 2026
Phase 2Active Not Recruiting
NCT05866510Chia Tai TianQing Pharmaceutical GroupUtidelone and anlotinib

Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer

Start: May 2023Est. completion: Apr 2024
Phase 2Unknown
NCT05247905Alliance Pharmaceuticalscapecitabine

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

Start: Feb 2023Est. completion: Oct 203331 patients
Phase 2Active Not Recruiting
NCT05007613IpsenCabozantinib 40 MG

Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Start: Jun 2021Est. completion: Dec 202424 patients
Phase 2Completed
NCT03818997RocheDKN-01

Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer

Start: Dec 2019Est. completion: Apr 20220
Phase 2Withdrawn
NCT01522768Boehringer IngelheimAfatinib and Paclitaxel

Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

Start: Mar 2012Est. completion: Feb 202342 patients
Phase 2Completed
NCT01032850Alliance Pharmaceuticalscapecitabine

Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma

Start: Sep 2009Est. completion: Aug 201715 patients
Phase 2Terminated
NCT00891878Alliance Pharmaceuticalscapecitabine

Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction

Start: Aug 2009Est. completion: Jan 201312 patients
Phase 2Completed
NCT00601627Alliance Pharmaceuticalscapecitabine

Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery

Start: Jun 2009Est. completion: May 201352 patients
Phase 2Completed
NCT00917462BayerSorafenib, administered orally

Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer

Start: Jun 2009Est. completion: Aug 201835 patients
Phase 2Completed
NCT00539617GenentechErlotinib

Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery

Start: Oct 2007Est. completion: May 20117 patients
Phase 2Terminated
NCT00450515Alliance Pharmaceuticalscapecitabine

Vinflunine and Capecitabine in Treating Patients With Previously Treated Metastatic Breast Cancer

Start: Mar 2007Est. completion: Jan 20090
Phase 2Withdrawn
NCT00394433GenentechBevacizumab

Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer

Start: Sep 2006Est. completion: Oct 201638 patients
Phase 2Completed
NCT00268437Alliance Pharmaceuticalscarboplatin

Radiation Therapy, Pemetrexed Disodium, and Carboplatin in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery

Start: Apr 2006Est. completion: Mar 201527 patients
Phase 2Terminated
NCT00100945Alliance Pharmaceuticalsgefitinib

Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer

Start: Jul 2005Est. completion: Oct 200970 patients
Phase 2Completed
NCT00256269SanofiOxaliplatin

Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma

Start: Jun 2005Est. completion: Feb 20074 patients
Phase 2Terminated
NCT00525915Sanofi5-Fluorouracil

Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma

Start: Apr 2005Est. completion: Mar 2013126 patients
Phase 2Completed
NCT00081224Alliance Pharmaceuticalscapecitabine

Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum

Start: Dec 2004Est. completion: Nov 20103 patients
Phase 2Terminated
NCT00093808Alliance Pharmaceuticalscapecitabine

Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer

Start: Aug 2004Est. completion: May 201347 patients
Phase 2Completed
NCT00054457Alliance Pharmaceuticalscapecitabine

Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction

Start: Sep 2003Est. completion: Feb 200846 patients
Phase 2Completed
NCT00042965Alliance Pharmaceuticalscapecitabine

Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer

Start: Oct 2002Est. completion: Sep 200660 patients
Phase 2Completed
NCT00022139Alliance Pharmaceuticalscarboplatin

Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Start: Jan 2002Est. completion: Jan 200956 patients
Phase 2Completed
NCT00017212Daiichi Sankyoexatecan mesylate

DX-8951f in Treating Patients With Metastatic Stomach Cancer

Start: Apr 2001Est. completion: Sep 2003
Phase 2Completed
NCT00004183Alliance Pharmaceuticalscapecitabine

Capecitabine in Treating Patients With Malignant Mesothelioma

Start: Nov 2000Est. completion: Jan 200627 patients
Phase 2Completed
NCT00139633Bristol Myers Squibbcarboplatin, 5FU, Taxol and radiation

Selective Dose Escalation for Esophageal Cancer

Start: Jul 2000Est. completion: Jun 200525 patients
Phase 2Unknown
NCT00005876Astex Pharmaceuticalsrubitecan

Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery

Start: Apr 2000
Phase 2Unknown
NCT00003137Alliance Pharmaceuticalsirinotecan hydrochloride

Irinotecan in Treating Patients With Advanced Cancer of the Stomach

Start: Dec 1997Est. completion: Jul 200470 patients
Phase 2Completed
NCT07367516Chia Tai TianQing Pharmaceutical GroupTQB6411 Injection

Clinical Trial Evaluating TQB6411 Injection in Subjects With Esophageal Cancer

Start: Feb 2026Est. completion: Mar 2027
Phase 1/2Recruiting
NCT04460066Lee's Pharmaceuticalanti-PD-L1 antibody

A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.

Start: Nov 2020Est. completion: Jul 202370 patients
Phase 1/2Unknown
NCT06760676Qilu PharmaceuticalPulsed low dose rate radiotherapy

A Multiple Tumor Species, Open and Multi-center Clinical Study of Alpaloritovorelli Antibodies (QL-1706) Combined with Pulsed Low Dose Rate External Irradiation (PLDR) for Disease Progression After Previous Anti-tumor Therapy

Start: Dec 2025Est. completion: Jul 2027
Phase 1Not Yet Recruiting
NCT05191667Adlai NortyeAN0025

AN0025 and Chemoradiotherapy Combination in Esophageal Cancer

Start: Jan 2022Est. completion: Dec 2025
Phase 1Suspended
NCT00566800City Therapeuticserlotinib hydrochloride

Erlotinib in Treating Patients With Barrett Esophagus

Start: Jul 2007
Phase 1Unknown
NCT00003704Alliance Pharmaceuticalscapecitabine

Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer

Start: Apr 1999Est. completion: Jul 200351 patients
Phase 1Completed
NCT06792786City TherapeuticsctDNA detection

Dynamic Changes of CtDNA to Evaluate the Efficacy of Immunoconsolidation Therapy After Radiotherapy and Chemotherapy for Esophageal Cancer

Start: Dec 2024Est. completion: Dec 2027
N/ARecruiting
NCT06499298Bristol Myers SquibbNivolumab

Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer

Start: Dec 2024Est. completion: Apr 202564 patients
N/ACompleted
NCT06335966Knight TherapeuticsScreening with swallowable esophageal cell-collection devices

BEST-RPP Pilot: Screening for Esophageal Cancer in Rural Oregon Without an Endoscopy

Start: Sep 2024Est. completion: Dec 2026110 patients
N/AActive Not Recruiting
NCT06895551GenomicsMethylation Biomarkers for Pioneering Early Esophageal Cancer Detection

Methylation Biomarkers for Pioneering Early Esophageal Cancer Detection

Start: Sep 2022Est. completion: Feb 20251,069 patients
N/ACompleted
NCT05431621GenomicsEstablishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers

Establishment of Molecular Classification Models for Early Diagnosis of Digestive System Cancers

Start: Nov 2020Est. completion: Jul 20232,430 patients
N/ACompleted
NCT04269083Verona PharmaBIRC3

A Biomarker-driven Therapeutic Strategy for Esophageal Cancer Chemoradiotherapy in Patients With Resectable Adenocarcinoma of the ESophagus and Esophagogastric Junction

Start: May 2020Est. completion: Aug 2024128 patients
N/AUnknown
NCT00642525Heidelberg PharmaContrast swallow radiography, endoscopy

Detection of Anastomotic Leakage After Esophageal Surgery

Start: Jan 2006Est. completion: Oct 200755 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
8m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
8m ago

Office Administrator

SystImmune
8m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
19m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
22m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
22m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 6,203 patients
22 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)